Archiving of biological material collected in patients with acute attack of thrombotic microangiopathy
Authors:
N. Chobolová 1,2; I. Hrachovinová 3,4; Z. Kořístek 2,5; M. Lánská 3,6; I. Demel 2,5; L. Brusová 2,5; L. Recová 2,7; P. Kovářová 2,8; J. Martínek 2,9; L. Broskevičová 2,5; M. Navratová 2,5; J. Svatošová 2,3,5; J. Gumulec 2,3,5; D. Stejskal 10
Authors‘ workplace:
Oddělení klinické bio chemie, Ústav laboratorní medicíny, FN Ostrava
1; Centrum pro trombotickém mikroangiopatie Ostrava
2; Česká skupina pro trombotické mikroangiopatie, z. s.
3; Laboratoř pro poruchy hemostázy, Ústav hematologie a krevní transfuze Praha
4; Klinika hematoonkologie LF OU a FN Ostrava
5; IV. interní hematologická klinika FN Hradec Králové
6; Oddělení klinické hematologie, Ústav laboratorní medicíny, FN Ostrava
7; Krevní centrum, FN Ostrava
8; Oddělení imunologie a alergologie, Zdravotní ústav se sídlem v Ostravě
9; Ústav laboratorní medicíny, FN Ostrava
10
Published in:
Transfuze Hematol. dnes,29, 2023, No. Supplementum 3, p. 16-21.
Category:
doi:
https://doi.org/10.48095/cctahd20233S16
Overview
Coordinated blood collection, pre-analytical processing, and storage of biological material at any time of the day or night is particularly important in patients with rapidly progressive disease, where initiation of treatment (e. g., plasmapheresis) before blood collection may affect laboratory results and complicate further differential diagnosis. Thrombotic microangiopathies belong to this group of diseases. In this article, we present a procedure tested in clinical practice at the University Hospital Ostrava. Next, the procedure was presented and discussed with experts from other haematology centres. The result of this discussion was the creation of a universal request form for the processing and archiving of blood samples, which may contribute to the standardization of the procedure in other medical institutions.
Keywords:
archiving of biological material – thrombotic microangiopathy – universal laboratory request form
Sources
1. Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008; 142 (5): 819–826. doi: 10.1111/j.1365-2141.2008.07276.x.
2. Clark WF, Huang SS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM. Plasmapheresis for the treatment of kidney diseases. Kidney Int. 2016; 90 (5): 974–984. doi: 10.1016/ j.kint.2016.06.009.
3. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol: CJASN. 2010; 5 (10): 1844–1859. doi: 10.2215/CJN.02210 310.
4. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol: JASN. 2007; 18 (8): 2392–2400. doi: 10.1681/asn.2006080811.
5. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Sem Thromb Hemost. 2010; 36 (6): 673–681. doi: 10.1055/s-0030-1262890.
6. Elliott MA, Letendre L, Gastineau DA, Winters JL, Pruthi RK, Heit JA. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol. 2010; 85 (1): 43–50. doi: 10.1111/j.1600-0609.2010.01448.x.
7. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012; 158 (3): 323–335. doi: 10.1111/j.1365-2141. 2012.09167.x.
8. Zini G, d‘Onofrio G, Briggs C, et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Labor Hematol. 2012; 34 (2): 107–116. doi: 10.1111/j.1751-553X.2011.01380.x.
9. Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016; 14 (Suppl 11): 2–15.
10. Williams LA, Marques MB, Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Pathology consultation on the diagnosis and treatment of thrombotic microangiopathies (TMAs). Am J Clin Pathol. 2016; 145 (2): 158–165. doi: 10.1093/ajcp/aqv086.
11. Shen YM. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thromb J. 2016; 14 (Suppl 1): 19. doi: 10.1186/s12959-016-0114-0.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2023 Issue Supplementum 3
Most read in this issue
- Evaluation of blood counts and schistocytes in the peripheral blood smear
- Complement system – disorders and diagnostics
- Thrombotic microangiopathies – availability of diagnostic methods and treatment options in the Czech Republic in 2021: results of a syndicated survey among clinical haematologists
- Hereditary thrombotic thrombocytopenic purpura